switching between tirzepatide and semaglutide to switching glp 1 agonists between

People with Type 2 diabetes might not produce enough GLP-1, or its effects might be too weak

Like all prescription medicines, semaglutide tablets can cause side effects , most commonly affecting the digestive system, particularly during the early stages of treatment or after a dose increase

They have metabolic, structural, homeostatic, and neuropro-tective functions, and possess a remarkable role in maintaining blood brain barrier (BBB) [9]

Compounded medications, when prescribed, are not FDA-approved and are not reviewed by the FDA for safety, effectiveness, or quality

It does not predict exact discontinuation outcomes but supports a more personalized provider conversation about your metabolic risk profile

Individuals with minimal weight to lose (BMI under 27 kg/m without comorbidities) do not meet clinical criteria for pharmacological weight loss treatment